广东省人民医院的吴一龙教授与澳大利亚的Benjamin J. Solomon、韩国的Dong-Wan Kim等进行的这项III期PROFILE 1014 试验在间变性淋巴瘤激酶(ALK)阳性晚期非鳞状非小细胞肺癌患者中比较了crizotinib与化疗作为一线治疗的疗效,并报告了最终总生存(OS)结果...
被点评研究:Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALKPositive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol 2016;34:2858-65. PROFILE 1014中克唑替尼颅内疗效对比化疗:关注临床试验中的中枢神经...
PS-1FIRST-LINE CRIZOTINIB VS PEMETREXED + CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK+ NSCLC IN PROFILE 1014doi:10.1093/annonc/mdu395.1Nakagawa, KazuhikoKim, Dong-WanWu, Yi-LongSolomon, Benjamin J.Mekhail, TarekFelip, Enriqueta...
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non...
Background: The efficacy of the oral ALK inhibitor crizotinib (C) compared with pemetrexed-platinum chemotherapy (PPC) has been demonstrated in the first-line setting in patients with advanced ALK+ non–small-cell lung cancer (NSCLC). The primary objective, progression-free survival (PFS), for ...
[9] Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol 2016;34:2858-65. [10] Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and act...
Crizotinib, initially designed as c-MET inhibitor, is usually applied in patients with ALK arrangement due to its multi-target actions32. Onartuzumab, however, is a recombinant, humanized, monovalent, monoclonal antibody that binds with MET, thus preventing this receptor from com- bining with its ...
responses rates (ORR) and longer progression free survival (PFS) than the standard platinum doublet chemotherapy in those patients (median PFS: 10.9 vs . 7.0 months, respectively; hazard ratio for progression or death with crizotinib: 0.45; ORR: 74% vs . 45%, respectively) (PROFILE 1014) (...
被点评研究:Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALKPositive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol 2016;34:2858-65. PROFILE 1014中克唑替尼颅内疗效对比化疗:关注临床试验中的中枢神经...